Lower serum IGF-1 levels at disease onset are associated with worse prognosis, increased cognitive impairment risk, and faster disease progression, suggesting that individuals who fail to exhibit an adequate IGF-1 increase experience poorer outcomes105,107. This evidence concerns the gene IGF1 and Cognitive impairment.